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Abstract
Urolithiasis or urinary stone disease has been estimated to affect about 1 in 11 Americans. Patients 
with urinary stone disease commonly present to the emergency department for management of 
their acute pain. In addition to providing analgesia, administration of drug (medical expulsive 
therapy) is often prescribed to assist passage of the urinary stone. In this methodology paper, we 
describe the design of a prospective, multi-center, randomized, double-blind placebo controlled 
clinical trial of the alpha-adrenergic blocker, tamsulosin, to evaluate its effectiveness as medical 
expulsive therapy. In addition, we describe the unique challenges of conducting a trial of this type 
within the setting of the emergency department.
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Introduction
The prevalence of urolithiasis, or urinary stone disease (USD), is increasing among adults 
and children in the United States1,2. It is estimated that USD affects about 1 in 11 people in 
the United States3. Because the most common symptoms of USD include severe flank and 
abdominal pain, nausea, vomiting and hematuria, patients often present to the emergency 
department (ED) for treatment. From 2006 to 2009 there were approximately 3.6 million 
visits to EDs in the United States for episodes of urinary stones4. In addition to the direct 
impact on the patient, including recurrent episodes3, the cost of treating urinary stones is 
substantial. Charges for ED visits for this condition were $5 billion in 20094.
While relieving acute pain is the immediate goal in the management of urinary stone disease 
in the ED, the use of drugs to promote passage of the stone(s), or medical expulsive therapy 
(MET), has also been advocated. Guidelines, based primarily on randomized clinical trials 
with a small sample size5,6, recommend the use of MET to promote stone passage7,8. 
Among the drugs believed to promote urinary stone passage, the class of alpha-adrenergic 
receptor blockers (alpha-blockers) has been studied most often. A recent Cochrane 
Collaboration review of 32 randomized clinical trials of this drug class concluded “the use of 
alpha-blockers in patients with ureteral stones results in a higher stone-free rate and shorter 
time to stone expulsion…and should therefore be offered as part of medical expulsive 
therapy as one of the primary treatment modalities”9. However, two recent, large-scale 
clinical trials10,11 failed to show a benefit of the alpha-blocker tamsulosin (the latter also 
failed to show a benefit of the calcium channel blocker nifedipine) to promote passage of 
urinary stones compared to placebo and have called into question the use of MET12.
We describe the design of a multi-center, randomized, placebo controlled, double-blinded 
trial of tamsulosin in patients with urinary stones presenting to the ED (the Study of 
Tamsulosin for Urolithiasis in the Emergency Department-STONE) to evaluate its effect on 
the passage rate over a 28-day period of treatment. We also describe several challenges 
encountered conducting this trial in the ED setting.
Materials and Methods
Study Design
Men and women, 18 years of age or older, presenting to participating EDs with signs and 
symptoms of urinary stones are screened. Those with evidence of USD based on computed 
tomography (CT) imaging meet with study staff to review inclusion and exclusion criteria 
(Table 1). Eligible persons who consent to participate are randomized via a web-based 
system, stratified by clinical site, to either 0.4mg Tamsulosin or matching placebo using the 
simple urn method13. Participants are instructed to take their assigned medication once daily 
for 28 days. The need for medical follow-up and the use of analgesic medications are based 
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on standard clinical care at the participating EDs. The study protocol was approved by the 
Institutional Review Boards of the participating institutions. All participants provided 
written informed consent.
The primary outcome of this trial is stone passage, determined either by visualization or 
capture by the study participant, within 28 days of randomization. Secondary outcomes are: 
(1) time from randomization to urinary stone passage; (2) surgical intervention or lithotripsy; 
(3) complications related to the urinary stone(s) including hospitalizations; (4) length of time 
in pain; (5) days of work lost; (6) amount of analgesia taken (7) overall costs; (8) urinary 
stone passage confirmation on CT scan; and, (9) crossover to open label tamsulosin during 
follow-up.
Participants are contacted via phone five times during the first 30 days after randomization 
(days 2, 7, 15, 20 and 29) to obtain follow-up and outcome information and again at 90 days 
post-randomization (Table 2).
Statistical Considerations
The sample size was based on information published in a meta-analysis on the urinary stone 
passage rate available at the time the study was planned5. This metaanalysis reported a 
urinary stone passage rate that varied between 20% and 73% across the studies considered. 
Employing a two group Pearson chi-squared test with a 0.05 two-sided significance level, 
we estimated that a total sample size of 500 patients equally randomized to drug and placebo 
would result in a 90% power to detect the difference between a placebo passage rate of 45% 
and a drug passage rate of 60%.
During the initial planning phase of the trial an independent Data and Safety Monitoring 
Board (DSMB) was established by the sponsor, the National Institute of Diabetes and 
Digestive and Kidney Diseases (NIDDK). The DSMB initially served as a protocol review 
committee, providing input on study design, and recommended a single-site pilot study to 
assess feasibility. As part of the assessment of feasibility, the DSMB recommended that the 
urinary stone passage rate among participants randomized to the placebo group be 
determined after 100 participants were randomized in the pilot study since the rates in the 
published literature varied widely. This review confirmed the original target sample size of 
500 and led to an expansion of the study to additional EDs. Recruitment for the multi-center 
trial was initiated in August 2013 and completed in October 2016. The initial 100 patients 
enrolled in the pilot are included in the target sample size of 500 allowing for losses to 
follow-up. If covariate adjustment is necessary, logistic regression will be used.
Secondary time to event outcomes will be analyzed using life-table analyses (time to stone 
passage and time in pain). Secondary dichotomous outcomes (confirmation of stone passage 
status on CT, need for surgical intervention or lithotripsy, repeat ED visits or other 
hospitalizations, crossover to open label tamsulosin, return to work, side effects, adverse 
events) will be analyzed using standard parametric and nonparametric statistical techniques, 
such as the Chi-square test.
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Categorical outcomes (number of days lost from work, amount of analgesia taken, steroids 
taken or contraindicated medications) will be analyzed using Poisson regression with 
adjustment for covariates if necessary. Continuous variables will be analyzed using general 
linear models.
Challenges to Conducting the Study in the Emergency Department
A number of unique challenges, which may apply to other types of ED clinical research 
studies, were encountered in the STONE Study (Table 3). While these challenges primarily 
relate to engaging the participant during the recruitment process, they also have 
consequences for adherence to the study protocol, including the post-ED treatment regimen 
and data collection during follow-up. First, we recognized that in contrast to other types of 
clinical trials that may identify potential study participants in a non-acute illness state 
through physician referral, advertising, patient databases, etc., patients with USD present 
themselves to the ED in need of immediate care, especially pain relief. Thus, the willingness 
of a person with urinary stones in acute distress to be enrolled in a clinical trial may be 
reduced significantly. Second, there may be limited time between when both the pain is 
controlled and a diagnosis of USD is confirmed and when the patient is discharged from the 
ED. Consequently, study staff may have limited time to explain the study to the patient, 
answer questions about the demands of the trial, and obtain written informed consent. This 
time pressure is exacerbated by the fact that the ED encounter is the only opportunity for 
eligibility screening and randomization. Because there may be insufficient time to establish a 
“personal” relationship with the potential study participant, the expectation of adherence to 
treatment and need for follow-up contact (only remote follow-up contact is performed) may 
not be as firmly established as in other recruitment settings. Third, study staff must 
collaborate with other ED staff, urologists and radiologists to avoid treatment with the study 
drug or other contraindicated medications, to identify subjects with planned intervention or 
hospitalization for urinary stones, and to be aware of the need for CT imaging as a 
prerequisite for inclusion. Finally, initial interest in participation may wane after discharge 
from the ED and resolution of symptoms thereby hindering follow-up contacts and the 
ability to obtain the primary outcome. Although not specific to the ED, the unwillingness to 
use CT scan as the primary imaging study for abdominal pain suspected to be caused by a 
stone by physicians and patients was another challenge.
Discussion
The STONE Study is the first large-scale multi-center clinical trial of MET in the United 
States. The decision to evaluate the alpha-adrenergic blocker tamsulosin was based on the 
benefits of this drug to promote urinary stone passage shown in previous small clinical trials, 
a low frequency of adverse events, and ease of dosing (no titration)5,14,15.
Although guidelines for the use of MET have been established, it has recently been shown to 
be used in about only one in five patients in the United States with urinary stones3,16. The 
reason(s) for this low rate is unclear. Recently, two large clinical trials of MET found no 
benefit overall10,11. Among 1,167 participants with a single urinary stone presenting to 24 
hospitals in the United Kingdom (the Spontaneous Urinary Stone Passage Enabled by Drugs 
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–SUSPEND Trial) randomized to either tamsulosin, nifedipine or placebo, no significant 
difference in the proportion of patients requiring further intervention at 4 weeks was 
observed10. An Australian study of 403 patients presenting to five EDs found no significant 
difference in the rate of urinary stone passage at 28 days among persons randomized to 
tamsulosin compared to placebo11. However, in a planned subgroup analysis (n=77) of 
patients with large urinary stones (5 to 10 mm), the passage rate was significantly higher in 
patients assigned to tamsulosin (83.3%) than placebo (61.0%).
During the recruitment period of the STONE Study, the results of SUSPEND10 were 
reported to the DSMB. The DSMB recommended that the STONE Study continue to enroll 
participants as planned due to differences in the primary outcomes between SUSPEND 
(need for further intervention) and the STONE Study (self-reported stone passage). The 
DSMB also considered the results of the study by Furyk et. al.11 and concluded that the 
STONE Study should continue to recruit to target goal given that most of the study 
participants had already been enrolled.
There are several notable features of the STONE study. First, our primary outcome of 
urinary stone passage is the most direct outcome for successful medical expulsive therapy. 
Second, the target sample size results in 90% statistical power to detect an absolute 
difference of the passage rate between drug and placebo of 15%. Third, the planned sample 
size was not altered after evaluating the passage rate of the placebo group after 100 
participants were enrolled in a pilot study. Fourth, regular telephone contact during follow-
up is intended not only to foster collection of necessary information on outcomes but also to 
promote treatment adherence. Fifth, when possible, our primary outcome of self-reported 
urinary stone passage is confirmed by a repeat CT scan at Day 29. Finally, given the 
substantial number of patients seen annually in EDs for urinary stones, the use of the ED site 
for study recruitment is appropriate. In conclusion, the results of this trial will add high level 
evidence to inform the use of MET with an alpha-adrenergic receptor blocker in the clinical 
management of patients with urinary stone disease seen at the time of presentation of acute 
symptoms.
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Table 1
Inclusion and Exclusion Criteria
Inclusion Criteria
• Age ≥ 18 years
• Evidence of ureterolithiasis on CT, which does not include stones located solely in the kidney
• Willingness to participate and able to proceed with standard outpatient management
• Has a telephone in order to be contacted for follow-up.
Exclusion Criteria
• Desire or need for immediate surgical intervention
• Current urinary tract infection (based on clinical symptoms, urine dipstick, or urinalysis)
• Known anatomical genitourinary abnormalities or prior genitourinary surgeries
• Known or suspected pregnancy
• Breastfeeding mothers
• History of hypersensitivity to Tamsulosin
• Current use of any alpha blockers or calcium channel blockers
• Current use of steroids (may have an independent effect on stone expulsion)
• Spontaneous stone expulsion prior to discharge from the ED
• Largest stone dimension greater than or equal to 9mm on CT scan
• Previous treatment for the current ureteral stone
• Ipsilateral, transplanted or solitary kidney (hospitalization may be necessary)
• Known renal insufficiency
• Fever >101.5°F
• Tamsulosin contraindications:
◦ Current use of vardenafil
◦ Floppy iris syndrome
◦ Planned cataract surgery in the next 60 days
• Prisoners/wards of state
• Prior enrollment in the study
• Non-English speaker due to telephone follow-up
• Bladder stone (any stone in the bladder)
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Table 3
Challenges Encountered
Challenge Reason Approach to Mitigate
Missing disqualifying criteria
in potential study
participants (possible
protocol violation)
Information presented by
patient in pain, not having the
ability to access all patient
medical records in a timely
manner.
Systematic approaches to
identifying all potentially
eligible persons (e.g., electronic
database). Continuous
communication with treating
physicians about study
eligibility criteria.
Recruitment including
explaining the study and
obtaining informed consent
Potential participant is
experiencing pain. Short period
of time between confirmation
of diagnosis and discharge from
the ED
Careful assessment of the state
of the patient by study team
(ability to comprehend).
Revisiting the requirements
of the study during follow-up
contacts (including treatment
regimen, contact schedule
and follow-up CT)
Randomized participant may
see little value in follow-up
treatment if acute pain episode
resolves. Little opportunity to
forge relationship with study
team during screening.
Clear explanation of the
importance of urinary stone
passage and potential benefit of
study drug to promote passage
at screening and subsequent
contacts. Incentives (e.g.,
monetary) following contacts
and/or follow-up CT.
Collaboration of specialties
(emergency medicine,
urology, radiology)
Recruitment depends on
identifying patients who are not
taking tamsulosin, not being
admitted and not planning to
receive an intervention.
Follow-up CT needs to be
coordinated.
Build strong relationships with
other health care workers
within the ED.
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